Harrow (Nasdaq: HROW), a Nashville-based ophthalmic disease management company, has announced the re-launch of VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1%, a prescription therapy indicated for vernal keratoconjunctivitis (VKC) in pediatric patients. The move is positioned by the company as a direct response to unmet clinical need in specialized eyecare — a therapeutic niche that sits firmly within the Rx pharmaceutical channel rather than the functional foods or nutraceutical market.
It is worth noting for Functional News readers that VERKAZIA is a prescription pharmaceutical product regulated under FDA drug approval pathways, not a dietary supplement, nutraceutical, or functional food ingredient. Cyclosporine in this context does not carry a GRAS (Generally Recognized as Safe) designation, is not subject to New Dietary Ingredient (NDI) notification requirements, and does not support structure-function claims permissible under DSHEA. There is no applicable finished formulation, white-label, or co-manufacturing angle relevant to the functional foods and nutraceutical supply chain.
VKC is a chronic, severe form of allergic conjunctivitis that disproportionately affects children, particularly in warm climates. While the ocular allergy category does intersect, at its periphery, with the consumer wellness space — including omega-3 fatty acids, lutein, zeaxanthin, and other ingredients with eye-health structure-function claims — the clinical endpoint addressed by VERKAZIA is a pharmaceutical-grade immunosuppressive response not achievable through over-the-counter or supplement-channel interventions.
Operators and formulators active in the eye health and vision support segment should be aware that the re-launch may nonetheless elevate consumer and clinician awareness of pediatric ocular inflammation broadly, potentially creating downstream interest in evidence-backed nutritional support products. The nutraceutical eye-health category, anchored by carotenoids and marine-derived omega-3s, continues to grow as a complementary — not competitive — space to prescription ocular therapies.
Functional News will continue to monitor developments where the pharmaceutical and nutraceutical channels intersect, particularly as ingredient science around inflammation modulation and immune support advances. This re-launch, while outside our core coverage mandate, is flagged here as context for the broader pediatric health and ocular wellness conversation operators are navigating in 2026.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.